ASLAN Pharmaceuticals (ASLAN; 6497.TT), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that it has successfully concluded an initial public offering (IPO) of common shares via public lottery.
The shares were 29.4 times oversubscribed. 2,602,000 shares were made available for the public draw at the offer price of NT$68.92.
ASLAN has raised a total of NT$1 billion (US$33 million) from the IPO process. Trading of shares on the Taipei Exchange (TPEx) will commence on 1 June 2017.